March 2014

Scoring Systems for Blistering Diseases in PracticeWhy Bother, and Which One Should You Use?

Author Affiliations
  • 1Department of Dermatology, St George Hospital, Sydney, Australia
  • 2Faculty of Medicine, University of New South Wales, Sydney, Australia
  • 3Department of Dermatology, Keio University, Tokyo, Japan
  • 4Department of Dermatology, Philadelphia Department of Veterans Affairs, Philadelphia, Pennsylvania
  • 5Department of Dermatology, University of Pennsylvania, Philadelphia

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2014;150(3):245-247. doi:10.1001/jamadermatol.2013.8179

In most countries, pemphigus is one of those rare, potentially life-threatening skin and mucosal diseases that is referred to specialist centers for treatment. Because it is rare, there is a paucity of randomized clinical trials (RCTs) to inform dermatologists of the most effective and safe treatments.1 For rare diseases, meta-analysis, a statistical tool that allows pooling together the results of smaller, similar clinical trials, can be just as valuable as larger clinical trials, but in order to pool the data the studies need to use the same outcome measures for disease assessment.

First Page Preview View Large
First page PDF preview
First page PDF preview